TARSUS PHARMACEUTICALS, INC. Research and Development Expense
TARSUS PHARMACEUTICALS, INC. (TARS) reported Research and Development Expense of $31.01 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-06
- TARSUS PHARMACEUTICALS, INC. research and development expense for the quarter ending 2026-06-30 was $31.01M, a 98.86% increase year-over-year.
- TARSUS PHARMACEUTICALS, INC. research and development expense for the quarter ending 2026-03-31 was $22.35M, a 55.12% increase year-over-year.
- TARSUS PHARMACEUTICALS, INC. research and development expense for the quarter ending 2025-12-31 was $18.04M, a 6.89% increase year-over-year.
- TARSUS PHARMACEUTICALS, INC. research and development expense for the quarter ending 2025-09-30 was $16.28M, a 34.27% increase year-over-year.
- TARSUS PHARMACEUTICALS, INC. research and development expense for fiscal 2025 was $64.32M, a 20.48% increase from fiscal 2024.
- TARSUS PHARMACEUTICALS, INC. research and development expense for fiscal 2024 was $53.39M, a 6.11% increase from fiscal 2023.
- TARSUS PHARMACEUTICALS, INC. research and development expense for fiscal 2023 was $50.31M, a 18.04% increase from fiscal 2022.
- TARSUS PHARMACEUTICALS, INC. research and development expense for fiscal 2022 was $42.62M, a 2.19% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $31.01M 10-Q · filed 2026-08-06 | $53.36M 10-Q · filed 2026-08-06 | $71.40M derived: sum of 3 quarters · filed 2026-08-06 | $87.68M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $22.35M 10-Q · filed 2026-05-06 | $40.39M derived: sum of 2 quarters · filed 2026-05-06 | $56.67M derived: sum of 3 quarters · filed 2026-05-06 | $72.26M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $18.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $34.32M derived: sum of 2 quarters · filed 2026-02-23 | $49.91M derived: sum of 3 quarters · filed 2026-08-06 | $64.32M 10-K · filed 2026-02-23 |
| 2025-09-30 | $16.28M 10-Q · filed 2025-11-04 | $31.88M derived: sum of 2 quarters · filed 2026-08-06 | $46.29M 10-Q · filed 2025-11-04 | $63.16M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $15.59M 10-Q · filed 2026-08-06 | $30.00M 10-Q · filed 2026-08-06 | $46.88M derived: sum of 3 quarters · filed 2026-08-06 | $59.00M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $14.41M 10-Q · filed 2026-05-06 | $31.28M derived: sum of 2 quarters · filed 2026-05-06 | $43.41M derived: sum of 3 quarters · filed 2026-05-06 | $55.73M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $16.87M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $29.00M derived: sum of 2 quarters · filed 2026-02-23 | $41.32M derived: sum of 3 quarters · filed 2026-02-23 | $53.39M 10-K · filed 2026-02-23 |
| 2024-09-30 | $12.13M 10-Q · filed 2025-11-04 | $24.45M derived: sum of 2 quarters · filed 2025-11-04 | $36.51M 10-Q · filed 2025-11-04 | $49.82M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-06-30 | $12.32M 10-Q · filed 2025-08-06 | $24.39M 10-Q · filed 2025-08-06 | $37.69M derived: sum of 3 quarters · filed 2026-02-23 | $49.80M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-03-31 | $12.07M 10-Q · filed 2025-05-01 | $25.37M derived: sum of 2 quarters · filed 2026-02-23 | $37.48M derived: sum of 3 quarters · filed 2026-02-23 | $50.02M derived: sum of 4 quarters · filed 2026-02-23 |
| 2023-12-31 | $13.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $25.41M derived: sum of 2 quarters · filed 2026-02-23 | $37.96M derived: sum of 3 quarters · filed 2026-02-23 | $50.31M 10-K · filed 2026-02-23 |
| 2023-09-30 | $12.11M 10-Q · filed 2024-11-13 | $24.65M derived: sum of 2 quarters · filed 2024-11-13 | $37.01M 10-Q · filed 2024-11-13 | $47.03M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $12.55M 10-Q · filed 2024-08-08 | $24.90M 10-Q · filed 2024-08-08 | $34.93M derived: sum of 3 quarters · filed 2025-02-25 | $45.84M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $12.36M 10-Q · filed 2024-05-08 | $22.38M derived: sum of 2 quarters · filed 2025-02-25 | $33.30M derived: sum of 3 quarters · filed 2025-02-25 | $42.90M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $10.03M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $20.94M derived: sum of 2 quarters · filed 2025-02-25 | $30.54M derived: sum of 3 quarters · filed 2025-02-25 | $42.62M 10-K · filed 2025-02-25 |
| 2022-09-30 | $10.91M 10-Q · filed 2023-11-09 | $20.52M derived: sum of 2 quarters · filed 2023-11-09 | $32.60M 10-Q · filed 2023-11-09 | $40.63M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $9.60M 10-Q · filed 2023-08-10 | $21.68M 10-Q · filed 2023-08-10 | $29.72M derived: sum of 3 quarters · filed 2023-08-10 | $39.93M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $12.08M 10-Q · filed 2023-05-09 | $20.12M derived: sum of 2 quarters · filed 2023-05-09 | $30.33M derived: sum of 3 quarters · filed 2023-05-09 | $37.53M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $8.04M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-17 | $18.25M derived: sum of 2 quarters · filed 2023-03-17 | $25.45M derived: sum of 3 quarters · filed 2023-03-17 | $41.71M 10-K · filed 2023-03-17 |
| 2021-09-30 | $10.21M 10-Q · filed 2022-11-09 | $17.41M derived: sum of 2 quarters · filed 2022-11-09 | $33.67M 10-Q · filed 2022-11-09 | $41.26M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $7.20M 10-Q · filed 2022-08-11 | $23.46M 10-Q · filed 2022-08-11 | $31.05M derived: sum of 3 quarters · filed 2022-08-11 | $39.04M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $16.26M 10-Q · filed 2022-05-11 | $23.85M derived: sum of 2 quarters · filed 2022-05-11 | $31.84M derived: sum of 3 quarters · filed 2022-05-11 | $33.58M derived: sum of 4 quarters · filed 2022-05-11 |
| 2020-12-31 | $7.59M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | $15.58M derived: sum of 2 quarters · filed 2022-03-14 | $17.32M derived: sum of 3 quarters · filed 2022-03-14 | $18.83M 10-K · filed 2022-03-14 |
| 2020-09-30 | $7.99M 10-Q · filed 2021-11-10 | $9.73M derived: sum of 2 quarters · filed 2021-11-10 | $11.24M 10-Q · filed 2021-11-10 | $11.94M derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | $1.74M 10-Q · filed 2021-08-05 | $3.25M 10-Q · filed 2021-08-05 | $3.95M derived: sum of 3 quarters · filed 2021-08-05 | $4.34M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | $1.51M 10-Q · filed 2021-05-11 | $2.21M derived: sum of 2 quarters · filed 2021-05-11 | $2.61M derived: sum of 3 quarters · filed 2021-05-11 | |
| 2019-12-31 | $697.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | $1.10M derived: sum of 2 quarters · filed 2021-03-31 | $3.16M 10-K · filed 2021-03-31 | |
| 2019-09-30 | $399.00K 10-Q · filed 2020-11-25 | $2.46M 10-Q · filed 2020-11-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |